Our Synthetic Vaccine Particles (SVP™) technology platform is highly flexible, holding the potential to incorporate a wide range of antigens and immunomodulators, for the development of products that either induce antigen-specific tolerance or activate the immune system.
SVP are designed to remain intact after injection into the body and accumulate selectively in lymphoid organs, such as the lymph nodes and spleen, where significant immune responses are coordinated.
Depending on the type of immunomodulator encapsulated by SVP, they are intended to induce a:
- tolerogenic response, for example to a biologic drug to mitigate the formation of anti-drug antibodies (ADAs) or
- potent antigen-specific stimulatory response, such as an antibody response to a microbial antigen or a cytolytic T cell response to a tumor antigen.
Selecta’s primary focus is on developing and commercializing differentiated biologic therapies that avoid unwanted immune responses, enabling the safe and effective treatment of a range of rare and serious diseases. For instance, the company’s current proprietary pipeline includes product candidates for chronic severe gout, pancreatic cancer, mesothelioma and rare inborn errors of metabolism.
Potential components of SVP Products